BioCardia (BCDA)
(Delayed Data from NSDQ)
$2.54 USD
-0.44 (-14.77%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.57 +0.03 (1.18%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Income Statements
Fiscal Year end for BioCardia, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 1 | 0 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 12 | 13 | 14 | 16 | 15 |
Income After Depreciation & Amortization | -12 | -12 | -13 | -16 | -14 |
Non-Operating Income | 0 | 0 | 0 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -12 | -12 | -13 | -15 | -15 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -12 | -12 | -13 | -15 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -12 | -12 | -13 | -15 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -12 | -12 | -13 | -15 | -14 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -12 | -12 | -13 | -16 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.41 | 1.18 | 1.13 | 0.68 | 0.38 |
Diluted EPS Before Non-Recurring Items | -8.25 | -10.05 | -11.24 | -22.19 | -39.13 |
Diluted Net EPS (GAAP) | -8.25 | -10.04 | -11.24 | -22.19 | -39.13 |
Fiscal Year end for BioCardia, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.06 | 0.01 | 0.36 | 0.04 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.06 | 0.01 | 0.36 | 0.04 |
SG&A, R&D, and Dept/Amort Expenses | 1.65 | 2.33 | 2.10 | 2.95 | 3.49 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.65 | -2.27 | -2.09 | -2.59 | -3.45 |
Non-Operating Income | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.65 | -2.27 | -2.07 | -2.57 | -3.42 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.65 | -2.27 | -2.07 | -2.57 | -3.42 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.65 | -2.27 | -2.07 | -2.57 | -3.42 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.88 | 1.68 | 1.41 | 1.44 | 1.36 |
Diluted EPS Before Non-Recurring Items | -0.88 | -1.35 | -1.35 | -1.80 | -2.55 |
Diluted Net EPS (GAAP) | -0.88 | -1.35 | -1.35 | -1.80 | -2.55 |